Accessibility Statement

Press Releases


Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

February 7, 2025

Tags |  Product

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate multi-year,




FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

January 15, 2025

Tags |  Product

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remission and endoscopic response at one year, nearly 90% of patients maintained clinical remission with




FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

December 20, 2024

Tags |  Product

  Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated with OSA after one year INDIANAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:




Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

December 17, 2024

Tags |  Product

China is the fourth major market where Kisunla has received approval  Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 INDIANAPOLIS , Dec. 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today




Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

December 13, 2024

Tags |  Product

The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion  VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat symptom of bowel urgency using a patient-centric




Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

December 11, 2024

Tags |  Product

As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with  ESR1 mutations As combination therapy, imlunestrant plus Verzenio   significantly   reduced the risk of progression or death by 43%, compared to




Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting

December 9, 2024

Tags |  Product

Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib prolonged the time to next treatment or death by a median of 23.9 months compared to 10.9 months in the




CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade

December 9, 2024

Tags |  Product

Pro Football Hall of Famer Brian Dawkins joins the team to motivate those at risk for kidney disease to prioritize complete testing  LOS ANGELES , Dec. 9, 2024 /PRNewswire/ -- CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey,




Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

December 4, 2024

Tags |  Product

Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 receptor agonist in adults living with obesity without diabetes INDIANAPOLIS , Dec.




Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

November 18, 2024

Tags |  Product

Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the American Heart